A study from CHOP’s HI Center provides insights into how to best care for children with Kabuki syndrome and hyperinsulinism.

Facemasks accounted for over half of the top 10% of head impacts experienced by players in the study, highlighting the importance of prioritizing new helmet designs

Researchers from Children’s Hospital of Philadelphia (CHOP) announced findings from a new study that show outpatient diuretic use is common in children with bronchopulmonary dysplasia (BPD), and that factors such as gestational age, severity of BPD, and type of diuretic significantly influenced the timing of medication weaning. The study was published recently in Pediatric Pulmonology.

The ex vivo gene therapy improved sulfatase production and reduced symptoms associated with the disease in preclinical models

Researchers at CHOP announced the results of a new study offering insights into the development of next-generation gene therapies to treat hemophilia A.

Dr. Adam Wolpaw and Dr. Timothy Spear of Children's Hospital of Philadelphia (CHOP) received the Scholar Hope Award and Young Investigator Award respectively from Hyundai Hope On Wheels.

Energy drinks, marketed for boosting energy, concentration, and athletic performance, can pose significant cardiovascular risks, including death. Despite the American Academy of Pediatrics’ advice against caffeine consumption by children and adolescents, the United States remains the least regulated country and should take immediate steps to protect vulnerable populations, leading cardiology researchers at Children’s Hospital of Philadelphia (CHOP) urged in a recent commentary in the Journal of Pediatrics.

Check out our redesigned websites; learn about a new book to help families navigate vaccine decisions; and see updates related to RSV vaccine use in adults.

Dr. Lori Handy recounts a family’s experience with influenza. She also describes the symptoms of influenza and COVID-19 and talks about the importance of getting children vaccinated.

Researchers at Children’s Hospital of Philadelphia (CHOP) demonstrated a promising new approach in the fight against high-risk neuroblastoma, a common and potentially deadly childhood cancer that can occur within the peripheral nervous system. The study, recently published in Nature Communications, found that chimeric antigen receptor (CAR) T-cell therapy targeting two markers on neuroblastoma cancer cells simultaneously boosted overall immune response by engaging adaptive and innate immunity in preclinical models.